Page 108 - ADULT-ONSET ASTHMA PREDICTORS OF CLINICAL COURSE AND SEVERITY
P. 108
ADULT-ONSET ASTHMA – PREDICTORS OF CLINICAL COURSE AND SEVERITY
106
Table 2. Comparison Between Baseline and 5-year Follow-up Data.
BMI, kg/m2
ACQ-6 score
Inhaled steroid dose (fluticasone equiv)
28.6 ±5.5 28.7 1.32 ±0.93 1.08 313 (250-500) 250
±5.6 ±0.86 (0-500)
0.761 n=99 25.8 0.008 n=114 0.8 0.296 n=134 250
±3.4 26.5 ±0.71 0.23 (0-250) 0
±3.1 ±0.34 NA
pre FEV1 % predicted
post FEV1 % predicted
FEV1 % reversibility
post FEV1/VC% predicted
post DLCOcVA, % predicted post RV/TLC ratio, % predicted PC20-Methacholine, mg/ml
94 ±17 95 100 ±17 101 5 (2-9) 5 95 ±11 92 100 ±15 100 87 ±17 85 2.7 (0.8-6.6) 2.7
±19 ±19 (2-9) ±12 ±16 ±14 (1.2-16)
0.379 n=92 0.262 n=96 0.581 n=95 0.002 n=96 0.785 n=96 0.075 n=91 0.522 n=76
93 ±14 93 97 ±12 98 4 (2-6) 5 97 ±8 95 98 ±18 100 85 ±16 89 5.8 (2.9-32) 32
±13 ±12 (2-8) ±8 ±15 ±24 (5-32)
0.852 n=12 0.678 n=12 0.438 n=12 0.463 n=12 0.373 n=12 0.713 n=12 0.021 n=11
Asthma persistence (n=143) Baseline 5 years
Remission (n=27) p-value Baseline 5 years
p-value
0.071 n=12 0.002 n=18 <0.001 n=27
Total IgE, kU/L
FeNO, ppb
Blood neutrophils, 109/L
Blood eosinophils, 109/L
Sputum eosinophils, %
Sputum neutrophils, %
Pre: pre-bronchodilator. Post: post-bronchodilator. Data are presented as mean (±SD) or median (interquartile range).
59 (30-115) 98 29 (18-44) 26 3.0 (2.7-4) 3.5 0.15 (0.08-0.26) 0.18 0.6 (0.4-0.6) 0.6 63 (49-63) 54
(33-168) (14-31) (2.5-4.5) (0.1-0.27) (0.4-1.6) (34-70)
0.091 n=11 0.158 n=12 0.388 n=12 0.875 n=12 0.180 n=2 0.655 n=2
68 (26-236) 58 21 (13-45) 20 3.7 (3-4.6) 3.4 0.17 (0.1-0.28) 0.17 0.8 (0.2-4.2) 0.6 67 (50-77) 79
(21-177) (12-35) (2.7-4.2) (0.12-0.27) (0.2-2.8) (66-91)
0.268 n=95 0.371 n=94 0.369 n=96 0.489 n=97 0.200 n=45 0.001 n=45
2
